Kontafarma China Holdings (HKG:1312) expects a consolidated net loss between HK$79.2 million and HK$118.8 million in 2024, wider than the HK$61.1 million net loss in 2023, a Tuesday Hong Kong bourse filing said.

The pharmaceutical company attributed the anticipated increase to an impairment recognized on intangible assets associated with its fitness business, as well as the absence of a one-time gain from the disposal of subsidiaries, which had been recorded during the same period last year.

Shares of the company were down nearly 7% in recent trade.